Halozyme Therapeutics, Inc.
HALO
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other tā¦ read more
Healthcare
Biotechnology
22 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$69.27
Price+4.51%
$2.99
1Y
Price
Market Cap
$8.216b
Mid
Price/Earnings 3y Avg5y Avg
24.3x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+57.9%
EBITDA Margin+39.8%
Net Profit Margin+46.8%
Free Cash Flow Margin+57.9%
EBITDA Margin+39.8%
Net Profit Margin+46.8%
Free Cash Flow MarginRevenue
$1.508b
+8.0%
1y CAGR+22.7%
3y CAGR+23.4%
5y CAGREarnings
$348.843m
+10.1%
1y CAGR+13.1%
3y CAGR+19.6%
5y CAGREPS
$2.78
+8.6%
1y CAGR+15.5%
3y CAGR+23.1%
5y CAGRBook Value
$219.636m
$2.673b
Assets$2.453b
Liabilities$208.743m
DebtDebt to Assets
7.8%
0.2x
Debt to EBITDAFree Cash Flow
$667.654m
+3.6%
1y CAGR+22.2%
3y CAGR+31.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company